Contract Imaging Services at the Nikon BiolImaging Lab

Nikon BiolImaging Lab is a state-of-the-art facility located in Cambridge, Massachusetts, that provides advanced technologies to support the burgeoning regenerative medicine and biotech sector. At the lab, Nikon offers the expertise and equipment required to carry out simple to complex cell-based imaging assays. The facility is equipped to handle the complete assay process, cell thawing, expansion, differentiation, drug and toxicology screening, image data acquisition, and image data analysis.

For more information on Nikon’s contract imaging services, visit www.microscope.healthcare.nikon.com/bioimaging-lab
Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial

EUN HYE PARK,a HEE-SUK LIM,b SEUNGHEE LEE,c KYOUNGHWAN ROH,c KWANG-WON SEO,c KYUNG-SUN KANG,c,d KICHUL SHINb

Key Words. Clinical trial • Mesenchymal stem cell • Rheumatoid arthritis • Safety • Umbilical cord blood

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder that primarily involves synovial joints [1]. During the past decade, new classes of disease-modifying antirheumatic drugs (DMARDs) and updated treatment strategies enabled better clinical outcomes for RA patients, but few patients reach long-term drug-free clinical remission despite such achievements. Moreover, these approaches are costly and may ensue side effects, for instance, laboratory test abnormalities and serious infections [2, 3]. Therefore, the need still exists for an effective and safe treatment for those who respond inadequately to current therapies.

MSCs are mesoderm-derived cells that reside in the stroma of solid organs and function as precursors of nonhematopoietic connective tissues [4–6]. They can exert profound immunosuppression by modulating the proliferation and differentiation of T and B cells, dendritic cell maturation, and natural killer...
activity [6]. After in vivo administration, MSCs induce peripheral tolerance and migrate to injured tissues where they can inhibit the release of inflammatory cytokines and promote the survival of damaged cells [7]. Based on the immunoregulatory capabilities of MSCs, cell-based therapies using MSCs have been spotlighted as a promising tool for the treatment of various immune-related diseases, such as the graft-versus-host disease, inflammatory bowel disease, multiple sclerosis, and atopic dermatitis [8–12]. Some studies have also demonstrated that MSCs could be part of a new effective therapeutic approach for autoimmune arthritis [12–16].

The main sources of human MSCs are the bone marrow, peripheral blood, adipose tissue, and the umbilical cord. Compared with bone marrow-derived MSCs, human umbilical cord blood-derived MSCs (hUCB-MSCs) have distinct advantages, including accessibility, a higher proliferation capacity, and a lower immunogenicity [17]. In addition to well-documented self-renewal and multipotent differentiation properties, hUCB-MSCs possess immunoregulatory traits that permit allogeneic transplantation [18]. However, the role of hUCB-MSCs in vivo and their repair mechanisms in RA has not yet been fully elucidated.

To our knowledge, this is the first human trial that has investigated the outcome of hUCB-MSC infusions in patients with RA. A recent study used human umbilical cord (hUC)-derived MSCs to RA patients, which differ from hUCB-MSC in terms of source and preparation of the investigational product [19]. Our group has previously investigated the detailed mechanism by which hUCB-MSC infusions can ameliorate inflammatory arthritis [12]. This phase Ia study extends our preclinical research, investigating the safety and tolerability of a single intravenous infusion of hUCB-MSCs in Korean patients with RA.

**MATERIALS AND METHODS**

**Patient Population**

This study enrolled adults (>18 years) with RA who fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria [20] and had a baseline 28-joint count disease activity score (DAS28; using the erythrocyte sedimentation rate [ESR]) > 3.2. The requirement for all patients was to be on a stable dose of methotrexate (MTX), for at least 12 weeks. The exclusion criteria were as follows: a history of or current rheumatic diseases or an autoimmune joint disease other than RA, a functional class IV status as defined by the ACR Classification of Functional Status in RA [21], pregnancy or breastfeeding, a prior malignancy, or an active infection. Patients with a history of incompletely treated tuberculosis, or a conspicuous infection within 4 weeks before screening were also excluded.

**Study Design**

The Clinical and safety assessment of human Umbilical cord blood-derived mesenchymal stem cell therapy for RhEumatoid arthritis patients administered intravenously (CURE-iv) trial is a phase Ia, open-label, dose-escalation study for RA patients with a moderate disease activity despite treatment with MTX (ClinicalTrials.gov NCT02221258). The subjects were recruited from the Seoul Metropolitan Government-Seoul National University Boramae Medical Center. The study was approved by institutional review boards and ethics committees at Korea National Institute for Bioethics Policy, and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent before the investigation. Patients maintained their regimen of conventional DMARDs and oral corticosteroids (< 10 mg/day of prednisolone or its equivalent) throughout the study period.

The hUCB-MSCs were isolated and maintained as previously described [22]. Briefly, hUCB samples were obtained from the umbilical vein immediately after delivery and were mixed with Hetasep solution (StemCell Technologies, Vancouver, Canada) at a ratio of 5:1, and then incubated at room temperature. The supernatant was collected, and mononuclear cells were obtained using Ficoll (GE healthcare life sciences, Pittsburgh, PA) density-gradient centrifugation, according to the manufacturer’s protocol [23]. The cells were washed twice in phosphate buffered solution. Next, the cells were seeded at a density of $2 \times 10^5$ to $2 \times 10^6$ cells/cm$^2$ on plates in growth media that consisted of D-media (formula 78-5470EF; Gibco BRL, Grand Island, NY) containing EGM-2 SingleQuot and 10% fetal bovine serum (Gibco BRL). After 3 days, nonadherent cells were removed [24]. The stem cell characteristics of hUCB-MSCs were verified by determining their differentiation, proliferation, and immunological phenotypes as previously described [25]. The subjects were given a single intravenous infusion of $2.5 \times 10^7$, $5 \times 10^7$, or $1 \times 10^8$ cells of hUCB-MSCs for 30 minutes. Three patients were allocated to each cluster. The first cluster received the lowest cell number and then moved (increased hUCB-MSC numbers) to the next cluster if there was no dose-limited adverse event. Clinical and safety parameters were monitored after 24 hours, 72 hours, 1 week, and 4 weeks following the infusion (Fig. 1). Hematological and biochemical tests, urine analysis, chest radiography, and a 12-lead electrocardiogram (ECG) were performed. For the disease status assessment, values from a 66/68-swollen/tender joint count, DAS28, a pain visual analog scale (VAS), and a health assessment questionnaire (HAQ) were obtained. Serum cytokines, including IL-1β, IL-6, IL-8, IL-10, and TNF-α, at baseline and 24 hours after the infusion of hUCB-MSC were analyzed with a Human High Sensitivity T Cell Magnetic Bead Panel (Merck KGaA, Darmstadt, Germany).

**Outcomes**

The primary study objective was to evaluate the safety and tolerability of a single intravenous infusion of hUCB-MSCs in study subjects. The secondary objective was to obtain a preliminary assessment of its efficacy. For the efficacy end points, changes of DAS28 and HAQ 4 weeks after the infusion were evaluated.

**Statistical Analysis**

Continuous variables from the clinical data were presented as means and standard deviations. Discrete variables were reported as frequencies and proportions. The data for the safety evaluation before and after the treatment were compared by paired $t$ tests or the Wilcoxon signed-rank test. The statistical significance of the analyses’ results was determined by a two-tailed $p$ value of <.05.
RESULTS

Patient Characteristics

Out of the 11 screened RA patients, 9 were enrolled and received a single intravenous infusion of hUCB-MSCs (Fig. 2). The cell numbers of hUCB-MSCs infused to each patient were $2.5 \times 10^7$ ($n=3$), $5 \times 10^7$ ($n=3$), and $1 \times 10^8$ ($n=3$). The study subjects were predominantly female (78%) and the mean age was 57.4 years. The disease duration was (mean ± SD) 9.5 ± 8.7 years and the DAS28 at baseline was 4.53 ± 1.35. All subjects had received MTX, with mean doses of 14.2 mg/week at baseline and seven of them were taking oral corticosteroids (Table 1). No patient had previously received biologic DMARDs.

Safety and Tolerability

There was no ominous safety signal in all clusters up to 4 weeks after the infusion of hUCB-MSCs. The vital signs were stable during the hUCB-MSC infusion and clinically meaningful ECG changes could not be observed. Only one patient in the $5 \times 10^7$ group reported joint pain 60 minutes after the infusion, but this was determined to be unrelated to the hUCB-MSCs infusion. There was no major abnormal finding in the hematologic profiles (Table 2). Abnormalities were not observed in the serum chemical profiles such as of liver and renal functions. Serum uric acid levels were slightly elevated (from 3.63 ± 1.11 to 4.16 ± 1.19 mg/dl) at 4 weeks, but the changes were minor and there was no related adverse event. Neither serious adverse event nor dose-limiting toxicity (DLT) was reported.

Changes in Disease Activity

The ESR and C-reactive protein level changes from baseline to week 4 were $-7.9 \pm 10.4$ mm/hour ($p = .0517$) and $-0.37 \pm 1.09$ mg/dl ($p = .3362$), respectively (Table 2). At 4 weeks after the hUCB-MSCs infusion, the DAS28 reduction was statistically significant ($-1.60 \pm 1.57$ mm/hour, $p = .0158$; Table 1). The HAQ score and pain VAS changes at week 4 were $-0.15 \pm 0.48$ ($p = .3706$), and $-17.9 \pm 27.7$ ($p = .0885$), respectively. Serum levels of IL-1β, IL-6, IL-8, IL-10, and TNF-α...
Table 1. Baseline clinical and demographic characteristics of patients (n = 9)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 4</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>7 (77.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean ± SD, yr</td>
<td>57.4 ± 10.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration, mean ± SD, yr</td>
<td>9.5 ± 8.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, mean ± SD, kg/m²</td>
<td>25.2 ± 0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid factor, n (%)</td>
<td>6 (66.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CCP, positive, n (%)</td>
<td>4 (44.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX users, n (%)</td>
<td>9 (100.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose, mean ± SD, mg/wk</td>
<td>14.2 ± 0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroid users, n (%)</td>
<td>7 (77.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose, mean ± SD, mg/day</td>
<td>3.1 ± 0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swollen joint count, mean ± SD, n</td>
<td>2.4 ± 2.7</td>
<td>0.7 ± 0.8</td>
<td>1038</td>
</tr>
<tr>
<td>Tender joint count, mean ± SD, n</td>
<td>11.8 ± 16.7</td>
<td>2.0 ± 3.1</td>
<td>0.0888</td>
</tr>
<tr>
<td>DAS28-ESR, mean ± SD</td>
<td>4.53 ± 1.35</td>
<td>2.93 ± 1.22</td>
<td>0.0158</td>
</tr>
<tr>
<td>Pain VAS (0–100), mean ± SD, mm</td>
<td>64.8 ± 20.2</td>
<td>46.9 ± 29.1</td>
<td>0.0885</td>
</tr>
<tr>
<td>HAQ (0–5), mean ± SD</td>
<td>0.69 ± 0.63</td>
<td>0.54 ± 0.58</td>
<td>0.3706</td>
</tr>
</tbody>
</table>

*Prednisolone or its equivalent. Abbreviations: CCP, cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; DAS28, 28-joint disease activity score; VAS, visual analog scale; HAQ, health assessment questionnaire.

Table 2. Laboratory tests at baseline and week 4

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 4</th>
<th>Changes</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC, mean ± SD, x10³/mm³</td>
<td>7.99 ± 2.68</td>
<td>8.23 ± 3.30</td>
<td>0.23 ± 1.14</td>
<td>0.5555</td>
</tr>
<tr>
<td>ANC, mean ± SD, mm³</td>
<td>5,992.6 ± 2642.9</td>
<td>5,558.3 ± 2,793.4</td>
<td>434.2 ± 1,225.6</td>
<td>0.3594</td>
</tr>
<tr>
<td>Hematocrit, mean ± SD, %</td>
<td>38.5 ± 4.3</td>
<td>38.9 ± 4.8</td>
<td>0.3 ± 1.8</td>
<td>0.5852</td>
</tr>
<tr>
<td>Platelet, mean ± SD, mm³</td>
<td>292.1 ± 72.6</td>
<td>281.67 ± 78.8</td>
<td>−10.4 ± 22.2</td>
<td>0.1961</td>
</tr>
<tr>
<td>ESR, mean ± SD, mm/hr</td>
<td>23.3 ± 12.0</td>
<td>15.4 ± 9.2</td>
<td>−7.9 ± 10.4</td>
<td>0.0517</td>
</tr>
<tr>
<td>Hs-CRP, mean ± SD, mg/dl</td>
<td>0.81 ± 1.12</td>
<td>0.44 ± 0.47</td>
<td>−0.37 ± 1.09</td>
<td>0.3362</td>
</tr>
<tr>
<td>Total protein, mean ± SD, g/dl</td>
<td>6.74 ± 0.28</td>
<td>6.83 ± 0.53</td>
<td>0.09 ± 0.43</td>
<td>0.5537</td>
</tr>
<tr>
<td>Albumin, mean ± SD, g/dl</td>
<td>4.21 ± 0.14</td>
<td>4.19 ± 0.13</td>
<td>−0.02 ± 0.12</td>
<td>0.5943</td>
</tr>
<tr>
<td>Total bilirubin, mean ± SD, mg/dl</td>
<td>0.60 ± 0.17</td>
<td>0.61 ± 0.25</td>
<td>0.01 ± 0.19</td>
<td>0.8651</td>
</tr>
<tr>
<td>AST, mean ± SD, IU/l</td>
<td>20.2 ± 5.3</td>
<td>23.56 ± 9.7</td>
<td>3.33 ± 6.4</td>
<td>0.1570</td>
</tr>
<tr>
<td>ALT, mean ± SD, IU/l</td>
<td>17.0 ± 4.9</td>
<td>20.56 ± 10.6</td>
<td>3.56 ± 8.4</td>
<td>0.2390</td>
</tr>
<tr>
<td>BUN, mean ± SD, mg/dl</td>
<td>11.9 ± 2.6</td>
<td>13.2 ± 3.9</td>
<td>1.3 ± 3.6</td>
<td>0.2995</td>
</tr>
<tr>
<td>Creatinine, mean ± SD, mg/dl</td>
<td>0.66 ± 0.06</td>
<td>0.64 ± 0.09</td>
<td>−0.01 ± 0.09</td>
<td>0.6246</td>
</tr>
<tr>
<td>Glucose, mean ± SD, mg/dl</td>
<td>108.2 ± 12.9</td>
<td>104.6 ± 8.3</td>
<td>−3.7 ± 14.7</td>
<td>0.4566</td>
</tr>
<tr>
<td>Total cholesterol, mean ± SD, mg/dl</td>
<td>179.0 ± 30.5</td>
<td>186.3 ± 27.3</td>
<td>7.3 ± 16.4</td>
<td>0.2168</td>
</tr>
<tr>
<td>Triglyceride, mean ± SD, mg/dl</td>
<td>100.9 ± 29.6</td>
<td>126.8 ± 54.0</td>
<td>25.9 ± 63.9</td>
<td>0.2587</td>
</tr>
<tr>
<td>Uric Acid, mean ± SD, mg/dl</td>
<td>3.63 ± 1.11</td>
<td>4.16 ± 1.19</td>
<td>0.52 ± 0.57</td>
<td>0.0242</td>
</tr>
</tbody>
</table>

*Prednisolone or its equivalent. Abbreviations: ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate transaminase; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; Hs-CRP, high sensitivity C-reactive protein; MTX, methotrexate; WBC, white blood cell.

This phase Ia study demonstrated that a single intravenous infusion of hUCB-MSCs resulted in a favorable safety profile for our subjects with RA. The patients were given a single infusion of hUCB-MSCs, with cell numbers up to 1 x 10⁶ cells, yet inconsistent results were found in the cluster given 2.5 x 10⁷ or 5 x 10⁷ cells (Supporting Information Figure S2). A statistically significant increase in levels of IL-10, an immunosuppressive cytokine produced by regulatory T (Treg) cells, was discovered at 24 hours in the cluster infused with 5 x 10⁷ cells.

**DISCUSSION**

at baseline and 24 hours after the hUCB-MSCs infusion are depicted in Supporting Information Figure S1. Reduced levels of IL-1β, IL-6, IL-8, and TNF-α at 24 hours were observed in the cluster infused with 1 x 10⁶ cells, yet inconsistent results were found in the cluster given 2.5 x 10⁷ or 5 x 10⁷ cells (Supporting Information Figure S2). A statistically significant increase in levels of IL-10, an immunosuppressive cytokine produced by regulatory T (Treg) cells, was discovered at 24 hours in the cluster infused with 5 x 10⁷ cells.

This phase Ia study demonstrated that a single intravenous infusion of hUCB-MSCs resulted in a favorable safety profile for our subjects with RA. The patients were given a single infusion of hUCB-MSCs, with cell numbers up to 1 x 10⁶, and no DLT was reported. No major toxicity was observed up to 4 weeks after each infusion of hUCB-MSCs. With regard to efficacy assessment, disease activity change was not the primary objective of this study, but a single infusion of hUCB-MSCs reduced the mean DAS28 at week 4.

MSCs reportedly have the capabilities to modulate immune responses as well as to heal damaged tissues and organs [26]. They secrete a multitude of cytokines and growth factors with immunosuppressive properties, which inhibit B and T cell proliferation as well as monocyte maturation [6]. MSCs also promote the generation of Treg cells and M2 macrophages [27–29]. In addition, they are considered to possess a low immunogenicity due to their limited expression of the major histocompatibility complex (MHC) I, the lack of MHC expression as well as of costimulatory molecules, and the
inability to stimulate T cell activation [6, 30, 31]. Such results opened up the possibility for exploring the therapy and amelioration of immune-mediated disorders including graft-versus-host disease and autoimmunity disorders such as RA.

MSCs exert their therapeutic potential in a series of experimental arthritis by upregulating Treg cells and downregulating the expression of Th17 cells, which subsequently restores the immune function by inducing tolerance, promoting immune modulation, and reducing the release of inflammatory cytokines [14, 32–34]. Increasing evidence indicates the existence of a reciprocal relationship between Th17 cells and Treg cells; there is an inverse relationship between the transcription factor retinoic acid receptor-related orphan receptor C (for Th17 cells) and FoxP3 (for Treg cells) in the joints of patients with juvenile idiopathic arthritis [35]. MSC treatment reduces pathogenic T cell subsets, such as granulocyte macrophage colony-stimulating factor-expressing CD4 T cells, T follicular helper (Tfh) cells, and Th1/Th17 cells in the collagen-induced arthritis (CIA) model [36, 37]. Moreover, MSCs induce the apoptosis of activated T cells via the Fas ligand (FasL)/Fas signaling pathway in CIA [34]. MSCs overexpressing IL-10 have also attenuated CIA [38]. They inhibit the proliferation and expression of proinflammatory cytokines—such as interferon-γ and TNF-α—as well as the production of the matrix-degrading enzymes collagenase and gelatinase, which are involved in the inflammatory response within the synovium [39]. MSCs also prevent systemic bone loss in CIA via the direct inhibition of receptor activator of NF-KB ligand-induced osteoclastogenesis [40].

In vitro or preclinical studies have extensively examined the immunomodulatory actions of UCB-MSCs in RA. UCB-MSCs exert a profound inhibitory effect on the proliferation, invasive behavior, and inflammatory responses of fibroblast-like synoviocytes (FLSs) via IL-10, indoleamine 2,3-dioxygenase, and transforming growth factor β1. They also suppress T cell activations and induced the generation of Tregs [41]. A coculture of FLS with UCB-MSCs inhibited the expression of pro-inflammatory cytokines and chemokines IL-1β, IL-6, and the chemokine (C-C motif) ligand-2; it further induced FLS apoptosis and promoted chondrogenesis [42]. hUCB-MSCs downregulate the secretion of TNF-α from activated macrophages and also accelerated anti-inflammatory M2 polarizations in a paracrine manner [12]. In overall, hUCB-MSCs demonstrate a profound immune imbalance by downregulating the Th1 subset, decreasing the Th17 subset, inducing Tregs, and inhibiting the generation of Tfh cells which attenuate the severity of arthritis comparable to biologic treatments [43].

In a prior phase I study of hUCB-MSC infusions in Chinese patients with active RA, the subjects received 4 × 10^7 cells of hUCB-MSCs via an intravenous infusion, with some patients being additionally infused with hUCB-MSCs at 3-month intervals after the first treatment. The infusions were well tolerated and no major abnormalities were observed [19]. In our study, the patients were given a single infusion of hUCB-MSCs but a higher cell number of up to 1 × 10^8. However, no subjects exhibited an infusion reaction, a serious adverse event, or major abnormalities in serum chemical or hematologic profiles, both during and after the treatment. Although increased mean serum uric acid levels were observed, they were within the normal range, the changes were trivial, and no related AE was discovered throughout the study. Nevertheless, we plan to monitor serum uric acid levels in the future trials with repeated infusions. A randomized, placebo-controlled, phase Ib/IIa trial recently demonstrated the safety of repeated infusions (days 1, 5, and 18) of adipose-derived MSCs in patients with active RA; a trend for clinical efficacy was observed, yet it did not persist beyond 3 months after the infusion [16].

This study has some limitations. First, the sample size was relatively small and the duration of the follow-up period after the infusion of hUCB-MSCs was short for the exploration of long-term safety; we are currently conducting a 5-year observational study to search for any safety signal in our subjects. Also, there was no placebo group for further comparison with the hUCB-MSC recipients. Second, the administration of a single infusion of hUCB-MSCs is prohibitive in determining whether repetitive infusions would have similar safety outcomes. Third, among the study participants no one was exposed to biologic DMARDs; future trials are planned to be enrolled, if not limited to, previous biologic users. Lastly, although a range of clinical outcomes was assessed, imaging studies were excluded due to the short follow-up period. Future investigations including long-term radiographic outcomes in hUCB-MSC-treated patients would be interesting.

**CONCLUSION**

This is the first phase Ia study of RA patients that evaluated the safety and tolerability of a single intravenous infusion with hUCB-MSCs and with cell numbers of up to 1 × 10^8, revealing an acceptable safety profile. Conclusions regarding efficacy in phase I trials are limited, and although evaluation of disease activity was not the primary objective of this study, a single infusion of hUCB-MSCs effectively reduced the mean DAS28 at week 4. Considering favorable safety profiles, intravenous infusion of hUCB-MSCs may constitute a therapeutic option for patients with RA, who are refractory to or intolerant of MTX. There is a wide array of opportunities for future clinical studies with different hUCB-MSC infusion strategies in which safety profiles should be carefully monitored and outcome measures further refined for optimized effectiveness evaluations.

**ACKNOWLEDGMENTS**

We thank Junghyun Yoon for her help enrolling patients and conducting this trial.

**AUTHOR CONTRIBUTIONS**

E.H.P.: collection of data, data analysis and interpretation, manuscript writing, final approval of manuscript; H.-s.L.: collection of data, data analysis and interpretation; S.L.: data analysis and interpretation; K.R., K.-W.S., and K.-S.K.: conception and design, collection of data, data analysis and interpretation, manuscript writing, final approval of manuscript.
This study was funded by Kangstems Biotech Co., Ltd.; S.L., K.R., K.-W.S, and K.-S.K. work in the department of Stem Cell Therapy at Kangstems Biotech Co., Ltd. The other authors indicated no potential conflicts of interest.

REFERENCES

39. Gonzalez-Rey E, Gonzalez MA, Varela N et al. Human adipose-derived


See www.StemCellsTM.com for supporting information available online.